Table 2.

Setup of ‘real’ scenarios, mimicking previous immunotherapy studies

#	Scenario	Scenario analysis value(s)
A	Ipilimumab in melanoma [19], ipilimumab monotherapy arm	N = 137; utility data available for 54 months for all patients; pseudo-progression present (assumed 25% of long-term survivors) Age = 57; 59% male; survival plateau = 17%
B	Nivolumab in renal cell carcinoma [20], nivolumab monotherapy arm	N = 410; utility data available for 32 months for all patients Age = 62; 77% male; survival plateau = 20%
C	Pembrolizumab in non-small-cell lung cancer [21], pembrolizumab 3 weekly arm	N = 287; utility data available for 27 months for all patients Age = 64; 51% male; survival plateau = 30%
D	Atezolizumab in urothelial carcinoma [22], atezolizumab monotherapy arm	N = 467; utility data available for 23 months for all patients Age = 67; 76% male; survival plateau = 22%